Category | N = 495 |
---|---|
Age (years); mean ± SD [range] | 67.7 ± 8.98 [43–87] |
Age categories; n (%) | |
≥30 to < 65 | 164 (33.1) |
≥65 to < 85 | 325 (65.7) |
≥85 | 6 (1.2) |
Sex (M/F); n (%)a | 315 (63.6)/179 (36.2) |
Race: n (%) | |
White | 495 (100.0) |
Duration of Parkinson’s disease (months); | |
Mean ± SD | 102.1 ± 59.60 |
Median [range] | 89 [5–420] |
Duration of motor fluctuations (months); | |
Mean ± SD | 30.1 ± 37.97 |
Median [range] | 15 [0–324] |
Symptoms (WOQ-9 assessment); n (%)b | |
Tremor | 299 (62.7) |
Any slowness of movement | 459 (96.2) |
Mood changes | 248 (52.0) |
Any stiffness | 393 (82.4) |
Pain/aching | 286 (60.0) |
Reduced dexterity | 433 (90.8) |
Cloudy mind/slowness of thinking | 223 (46.8) |
Anxiety/panic attacks | 119 (24.9) |
Muscle cramping | 288 (60.4) |
Total levodopa daily dose (mg); mean ± SD | 580.1 ± 289.1 |
Median [range] | 525.0 [100–3750] |
Adjunct therapies; n (%)c | |
Rasagiline | 136 (27.5) |
Pramipexole | 123 (24.8) |
Ropinirole | 111 (22.4) |
Amantadine | 105 (21.2) |
Rotigotine | 68 (13.7) |
Safinamide | 67 (13.5) |
Piribedil | 44 (8.9) |